Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: Kinetics of neutropenia and thrombocytopenia and time-to-event results

Antonio Palumbo, Patrizia Falco, Antonietta Falcone, Giulia Benevolo, Letizia Canepa, Francesca Gay, Alessandra Larocca, Valeria Magarotto, Alessandro Gozzetti, Annalisa Luraschi, Fortunato Morabito, Andrea Nozza, Robert Knight, Jerome Zeldis, Mario Boccadoro, Maria Teresa Petrucci

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Initial analysis of the combination melphalan, prednisone, plus lenalidomide (MPR) showed significant antimyeloma activity in patients with untreated multiple myeloma, with neutropenia and thrombocytopenia as the most frequent side effects. This updated analysis reassessed the kinetics of neutropenia and thrombocytopenia as well as the safety and efficacy of MPR. Patients and Methods: A total of 21 patients with newly diagnosed myeloma received melphalan 0.18 mg/kg on days 1-4, prednisone 2 mg/kg on days 1-4, and lenalidomide 10 mg daily on days 1-21 for nine 28-day cycles, followed by maintenance therapy with lenalidomide 10 mg daily on days 1-21. Results: Grade 3/4 neutropenia occurred in 52% of the patients, and granulocyte colonystimulating factor was administered in 43%. The mean neutrophil counts at the start of each MPR cycle, during nadir, and after 6 months of maintenance were 2.69 × 109/L, 1.43 × 109/L, and 2.11 × 109/L, respectively. Grade 3/4 thrombocytopenia occurred in 24% of the patients. Platelet transfusions were required by 1 patient (5%) with a platelet count of 16 × 109/L; however, no thrombocytopenia-associated bleeding was reported. The mean platelet counts at the start of each cycle, during nadir, and after 6 months of maintenance were 174 × 109/L, 121 × 109/L, and 158 × 109/L, respectively. Median follow-up was 29.6 months, median progression-free survival was 28.5 months, and 2-year overall survival was 91%. Conclusion: MPR is a promising regimen with manageable hematologic toxicity.

Original languageEnglish
Pages (from-to)145-150
Number of pages6
JournalClinical Lymphoma and Myeloma
Volume9
Issue number2
DOIs
Publication statusPublished - 2009

Keywords

  • Elderly patients
  • Granulocyte colony-stimulating factor
  • Myelotoxicity
  • Neutropenia
  • Thrombocytopenia

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: Kinetics of neutropenia and thrombocytopenia and time-to-event results'. Together they form a unique fingerprint.

Cite this